Key result
Combined use of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists may provide additive antihypertensive, cardioprotective, and renoprotective effects in some patients.
Why the study?
Does the combined use of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 antagonists improve antihypertensive, cardioprotective, and renoprotective effects in patients with hypertension, renal disease, or congestive heart failure?
Does the combined use of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 antagonists improve antihypertensive, cardioprotective, and renoprotective effects in patients with hypertension, renal disease, or congestive heart failure?
Answers are grounded in this paper and cite their sources.
Preliminary evidence suggests potential additive benefits of combining ACE inhibitors and ARBs for hypertension, heart failure, and renal disease, but further studies are needed to confirm efficacy and identify optimal patient populations.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 antagonists have proven to be effective and well tolerated antihypertensive agents. They also exhibit unique cardioprotective and renoprotective properties in patients with comorbid conditions such as congestive heart failure and proteinuria or renal insufficiency. This benefit is observed most dramatically in diabetic persons. Although inconclusive, the results of a limited number of clinical trials support the notion that additive antihypertensive, cardioprotective, and renoprotective effects may be obtained with combined used of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 antagonists in some patients. More studies are needed to confirm the findings of these preliminary studies, and to define more clearly those subsets of patients who might derive the greatest benefit from angiotensin-converting enzyme inhibitor-angiotensin II receptor subtype 1 antagonist combination therapy.
No takes yet. Share an insight, caveat, or question.
Addison A. Taylor (2001) conducted a review in Hypertension, renal disease, or congestive heart failure. Combination of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 antagonists was evaluated. Combined use of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists may provide additive antihypertensive, cardioprotective, and renoprotective effects in some patients.
Synapse has enriched 10 related papers. Consider them for comparative context: